KRRO Korro Bio, Inc.
USHealthcareAs of 2026-10-09
Why KRRO matters now
Korro Bio, Inc. (KRRO) is a US stock in Healthcare. The latest InvestLog snapshot shows $10.16 with -3.97% on the session and $101.1M in market capitalization; recent performance reads 1-month +41.97% and YTD +62.17%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-19.6M, and EPS of $-1.69. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -54.6%.
The latest indexable market news headline is "Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $22.00; recent insider activity includes Dolan Oliver filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.26
P/S
33.65
EV/EBITDA
-1.41
DCF Value
$-0.48
FCF Yield
-54.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
73.2%
Operating Margin
-2154.0%
Net Margin
-2954.1%
ROE
-117.9%
ROA
-61.8%
ROIC
-48.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-19.6M | $-1.69 |
| Q4 2025 | $1.3M | $-50.0M | $-5.33 |
| FY 2025 | $6.4M | $-117.3M | $-12.48 |
| Q3 2025 | $1.1M | $-18.1M | $-1.92 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$19.57
Target (Median)
$22.00
Target Range
$10.00 - $30.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.10
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.